vs

Side-by-side financial comparison of Blue Bird Corp (BLBD) and CORCEPT THERAPEUTICS INC (CORT). Click either name above to swap in a different company.

Blue Bird Corp is the larger business by last-quarter revenue ($333.1M vs $202.1M, roughly 1.6× CORCEPT THERAPEUTICS INC). CORCEPT THERAPEUTICS INC runs the higher net margin — 12.0% vs 9.2%, a 2.8% gap on every dollar of revenue. On growth, CORCEPT THERAPEUTICS INC posted the faster year-over-year revenue change (11.1% vs 6.1%). CORCEPT THERAPEUTICS INC produced more free cash flow last quarter ($38.4M vs $31.1M). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs -1.9%).

The Blue Bird Corporation is an American bus manufacturer. Headquartered in Fort Valley, Georgia, the company was best known for its production of school buses. The company has also manufactured a wide variety of other bus types, including transit buses, motorhomes, and specialty vehicles such as mobile libraries and mobile police command centers.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

BLBD vs CORT — Head-to-Head

Bigger by revenue
BLBD
BLBD
1.6× larger
BLBD
$333.1M
$202.1M
CORT
Growing faster (revenue YoY)
CORT
CORT
+5.0% gap
CORT
11.1%
6.1%
BLBD
Higher net margin
CORT
CORT
2.8% more per $
CORT
12.0%
9.2%
BLBD
More free cash flow
CORT
CORT
$7.3M more FCF
CORT
$38.4M
$31.1M
BLBD
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
-1.9%
BLBD

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BLBD
BLBD
CORT
CORT
Revenue
$333.1M
$202.1M
Net Profit
$30.8M
$24.3M
Gross Margin
21.4%
98.7%
Operating Margin
11.3%
2.2%
Net Margin
9.2%
12.0%
Revenue YoY
6.1%
11.1%
Net Profit YoY
7.1%
-21.0%
EPS (diluted)
$0.94
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLBD
BLBD
CORT
CORT
Q4 25
$333.1M
$202.1M
Q3 25
$409.4M
$207.6M
Q2 25
$398.0M
$194.4M
Q1 25
$358.9M
$157.2M
Q4 24
$313.9M
$181.9M
Q3 24
$350.2M
$182.5M
Q2 24
$333.4M
$163.8M
Q1 24
$345.9M
$146.8M
Net Profit
BLBD
BLBD
CORT
CORT
Q4 25
$30.8M
$24.3M
Q3 25
$36.5M
$19.7M
Q2 25
$36.5M
$35.1M
Q1 25
$26.0M
$20.5M
Q4 24
$28.7M
$30.7M
Q3 24
$24.7M
$47.2M
Q2 24
$28.7M
$35.5M
Q1 24
$26.0M
$27.8M
Gross Margin
BLBD
BLBD
CORT
CORT
Q4 25
21.4%
98.7%
Q3 25
21.1%
97.8%
Q2 25
21.6%
98.2%
Q1 25
19.7%
98.5%
Q4 24
19.2%
98.4%
Q3 24
17.0%
98.4%
Q2 24
20.8%
98.5%
Q1 24
18.4%
98.3%
Operating Margin
BLBD
BLBD
CORT
CORT
Q4 25
11.3%
2.2%
Q3 25
12.3%
4.9%
Q2 25
12.6%
13.7%
Q1 25
9.4%
2.2%
Q4 24
10.5%
13.9%
Q3 24
7.3%
25.5%
Q2 24
11.9%
21.7%
Q1 24
10.4%
20.1%
Net Margin
BLBD
BLBD
CORT
CORT
Q4 25
9.2%
12.0%
Q3 25
8.9%
9.5%
Q2 25
9.2%
18.1%
Q1 25
7.3%
13.1%
Q4 24
9.2%
16.9%
Q3 24
7.0%
25.9%
Q2 24
8.6%
21.7%
Q1 24
7.5%
18.9%
EPS (diluted)
BLBD
BLBD
CORT
CORT
Q4 25
$0.94
$0.20
Q3 25
$1.11
$0.16
Q2 25
$1.12
$0.29
Q1 25
$0.79
$0.17
Q4 24
$0.86
$0.25
Q3 24
$0.71
$0.41
Q2 24
$0.85
$0.32
Q1 24
$0.79
$0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLBD
BLBD
CORT
CORT
Cash + ST InvestmentsLiquidity on hand
$241.7M
$372.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$271.4M
$647.8M
Total Assets
$642.3M
$836.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLBD
BLBD
CORT
CORT
Q4 25
$241.7M
$372.2M
Q3 25
$229.3M
$421.7M
Q2 25
$173.1M
$342.2M
Q1 25
$130.7M
$322.8M
Q4 24
$136.1M
$383.3M
Q3 24
$127.7M
$380.3M
Q2 24
$88.4M
$473.2M
Q1 24
$93.1M
$410.8M
Stockholders' Equity
BLBD
BLBD
CORT
CORT
Q4 25
$271.4M
$647.8M
Q3 25
$255.4M
$631.9M
Q2 25
$221.8M
$635.8M
Q1 25
$190.4M
$683.3M
Q4 24
$179.7M
$679.6M
Q3 24
$159.6M
$638.8M
Q2 24
$137.3M
$596.2M
Q1 24
$105.8M
$547.9M
Total Assets
BLBD
BLBD
CORT
CORT
Q4 25
$642.3M
$836.7M
Q3 25
$625.3M
$823.6M
Q2 25
$575.5M
$801.7M
Q1 25
$543.7M
$846.5M
Q4 24
$535.2M
$840.6M
Q3 24
$524.9M
$784.3M
Q2 24
$468.1M
$714.6M
Q1 24
$456.5M
$655.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLBD
BLBD
CORT
CORT
Operating Cash FlowLast quarter
$36.6M
$38.4M
Free Cash FlowOCF − Capex
$31.1M
$38.4M
FCF MarginFCF / Revenue
9.3%
19.0%
Capex IntensityCapex / Revenue
1.6%
0.0%
Cash ConversionOCF / Net Profit
1.19×
1.58×
TTM Free Cash FlowTrailing 4 quarters
$162.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLBD
BLBD
CORT
CORT
Q4 25
$36.6M
$38.4M
Q3 25
$65.1M
$54.5M
Q2 25
$56.9M
$43.9M
Q1 25
$27.8M
$5.1M
Q4 24
$26.4M
$59.3M
Q3 24
$55.4M
$73.8M
Q2 24
$989.0K
$41.2M
Q1 24
$54.6M
$23.8M
Free Cash Flow
BLBD
BLBD
CORT
CORT
Q4 25
$31.1M
$38.4M
Q3 25
$60.5M
Q2 25
$52.3M
$43.9M
Q1 25
$18.7M
$5.0M
Q4 24
$21.8M
$59.2M
Q3 24
$50.2M
$72.2M
Q2 24
$-3.5M
$40.8M
Q1 24
$51.8M
FCF Margin
BLBD
BLBD
CORT
CORT
Q4 25
9.3%
19.0%
Q3 25
14.8%
Q2 25
13.1%
22.6%
Q1 25
5.2%
3.2%
Q4 24
7.0%
32.5%
Q3 24
14.3%
39.5%
Q2 24
-1.1%
24.9%
Q1 24
15.0%
Capex Intensity
BLBD
BLBD
CORT
CORT
Q4 25
1.6%
0.0%
Q3 25
1.1%
0.0%
Q2 25
1.2%
0.0%
Q1 25
2.5%
0.1%
Q4 24
1.5%
0.1%
Q3 24
1.5%
0.9%
Q2 24
1.3%
0.3%
Q1 24
0.8%
0.0%
Cash Conversion
BLBD
BLBD
CORT
CORT
Q4 25
1.19×
1.58×
Q3 25
1.78×
2.77×
Q2 25
1.56×
1.25×
Q1 25
1.07×
0.25×
Q4 24
0.92×
1.93×
Q3 24
2.24×
1.56×
Q2 24
0.03×
1.16×
Q1 24
2.10×
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLBD
BLBD

Alternative Fuel Buses$151.4M45%
Diesel Buses$144.9M43%
Parts$24.8M7%
Other$12.1M4%

CORT
CORT

Segment breakdown not available.

Related Comparisons